[hmicms_related_articles] In summary, standard-dose apixaban for the treatment of atrial fibrillation in patients with ESRD may result in lower rates of major bleeding, stroke, and death compared ...

Please provide your email address to receive an email when new articles are posted on . Results published in the American Journal of Nephrology showed safe and effective outcomes when apixaban was ...

Apixaban, a Factor Xa inhibitor, was approved by the Food and Drug Administration (FDA) for use in patients with a creatinine clearance (CrCl) <15mL/min or those on dialysis based on ...

And although the current results suggest that NOACs offer a "potential benefit" over vitamin K antagonists, a retrospective study of apixaban in patients with ESRD and AF indicates there may be no ...

"These are the first data to show that apixaban is potentially safer than warfarin in dialysis patients with atrial fibrillation," says Siontis, who recently completed a cardiovascular fellowship ...

Apixaban may not prevent stroke in patients on maintenance dialysis patients who have new-onset nonvalvular atrial fibrillation, and it may increase the risk of bleeding, a new study suggests.

In a small study, apixaban showed promise as an alternative to warfarin in dialysis patients with calciphylaxis who require anticoagulation therapy. Apixaban, an anticoagulant used to treat venous ...

The research team tested whether apixaban could stop these clots from coming back after a thrombectomy, a procedure to remove the blockage. The study included 186 patients split into two groups ...

‘Apixaban drug has been found to be a low dose warfarin alternative to prevent stroke in dialysis patients.’ Patients who have kidney failure and are on dialysis were found to have a high ...

Dialysis patients with atrial fibrillation treated with apixaban blood thinner had a significantly lower risk of major bleeding with no difference in stroke found a recent study. Dialysis patients ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON ...